Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Similar articles for PubMed (Select 17344920)

1.

Expression and mutation status of candidate kinases in multiple myeloma.

Claudio JO, Zhan F, Zhuang L, Khaja R, Zhu YX, Sivananthan K, Trudel S, Masih-Khan E, Fonseca R, Bergsagel PL, Scherer SW, Shaughnessy J, Stewart AK.

Leukemia. 2007 May;21(5):1124-7. Epub 2007 Mar 8. No abstract available. Erratum in: Leukemia.2008 Apr;22(4): 889-90.

PMID:
17344920
2.

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.

Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, Barlogie B, Shaughnessy JD Jr, Stewart AK.

Blood. 2003 Jul 15;102(2):772-3. No abstract available.

3.

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.

Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Nakazawa N, Taniwaki M, Yawata Y, Ueki A.

Int J Oncol. 1999 Dec;15(6):1205-12.

PMID:
10568829
4.

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.

Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, Lombardi L, Neri A.

Oncogene. 2001 Jun 14;20(27):3553-62.

5.

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL.

Blood. 2001 Feb 1;97(3):729-36.

6.

Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.

Soverini S, Terragna C, Testoni N, Ruggeri D, Tosi P, Zamagni E, Cellini C, Cavo M, Baccarani M, Tura S, Martinelli G.

Haematologica. 2002 Oct;87(10):1036-40.

7.

The fibroblast growth factors in multiple myeloma.

Krejci P, Mekikian PB, Wilcox WR.

Leukemia. 2006 Jun;20(6):1165-8. No abstract available.

PMID:
16598309
8.

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.

Paterson JL, Li Z, Wen XY, Masih-Khan E, Chang H, Pollett JB, Trudel S, Stewart AK.

Br J Haematol. 2004 Mar;124(5):595-603.

PMID:
14871245
9.

t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients.

Winkler JM, Greipp P, Fonseca R.

Br J Haematol. 2003 Jan;120(1):170-1. No abstract available.

PMID:
12492597
10.

A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14).

Intini D, Baldini L, Lombardi L, Neri A.

Leukemia. 2002 Jun;16(6):1201-2. No abstract available.

11.

A molecular study of the t(4;14) in multiple myeloma.

Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ.

Br J Haematol. 2002 Aug;118(2):514-20.

PMID:
12139740
12.

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).

Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo AT, Neri A.

Br J Haematol. 2001 Aug;114(2):362-4.

PMID:
11529856
13.

Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers.

Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM, Riggins GJ, Wang TL, Yan H, Gazdar A, Kern SE, Pennacchio L, Kinzler KW, Vogelstein B, Velculescu VE.

Hum Mutat. 2006 Oct;27(10):1060-1.

PMID:
16941478
14.
15.

The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.

Fonseca R, Oken MM, Greipp PR; Eastern Cooperative Oncology Group Myeloma Group.

Blood. 2001 Aug 15;98(4):1271-2. No abstract available.

16.

PCR-based identification of new receptors: molecular cloning of a receptor for fibroblast growth factors.

Raz V, Kelman Z, Avivi A, Neufeld G, Givol D, Yarden Y.

Oncogene. 1991 May;6(5):753-60.

PMID:
1711190
17.

Very low mutation frequency of exons 5-9 in the CARD11 gene from 186 adult acute leukemia and 31 multiple myeloma samples.

Kim MS, Yoo NJ, Lee SH.

Leuk Res. 2011 May;35(5):e46-7. doi: 10.1016/j.leukres.2010.11.017. Epub 2010 Dec 19. No abstract available.

PMID:
21176849
18.

Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line.

Ronchetti D, Bogni S, Finelli P, Lombardi L, Otsuki T, Maiolo AT, Neri A.

Leukemia. 2001 May;15(5):864-5. No abstract available.

PMID:
11368454
19.

EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.

Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, Smith DL, Buscarini M, Broek D, Quinn DI, Weaver FA, Gill PS.

Oncogene. 2006 Feb 2;25(5):769-80.

PMID:
16205642
20.

FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.

Quintero-Rivera F, El-Sabbagh Badr R, Rao PN.

Cancer Genet Cytogenet. 2009 Nov;195(1):92-3. doi: 10.1016/j.cancergencyto.2009.06.018. No abstract available.

PMID:
19837276
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk